Malignant biphasic tumor of the uterus: A case report and review
- 37 Downloads
Abstract
We present a rare case of a 50-year old lady who presented with pain abdomen and bleeding per vaginum of 3 months duration. Per vaginal examination revealed an exophytic growth arising from vault. Histopathological examination of the vault biopsy showed malignant neoplasm with features suggestive of carcinosarcoma of vault with immunohistochemistry showing stromal cells positive for CD10 and negative for SMA. Ki67 index was 40%–50%. She received external beam radiotherapy to pelvis 50.4 Gy/25 fractions but did not respond to the same. The lesion was not surgically resectable and hence referred to the division of medical oncology for chemotherapy. She was started on ifosphamide with cisplatin with growth factor support. It was planned to do a reassessment after 3 cycles of chemotherapy, but patient succumbed to the illness.
Key words
carcinosarcoma uterus vaultPreview
Unable to display preview. Download preview PDF.
References
- 1.Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol, 2004, 93: 204–208.PubMedCrossRefGoogle Scholar
- 2.Jin Z, Ogata S, Tamura G, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol, 2003, 22: 368–373.PubMedCrossRefGoogle Scholar
- 3.Kuyumcuo>glu U, Kale A. Homologous type of malignant mixed Mullerian tumor of the uterus presenting as a cervical mass. J Chin Med Assoc, 2009, 72: 533–535.CrossRefGoogle Scholar
- 4.El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin Obst Gynecol, 2011, 54: 292–304.CrossRefGoogle Scholar
- 5.Schweizer W, Demopoulos R, Beller U, et al. Prognostic factors for malignant mixed müllerian tumors of the uterus. Int J Gynecol Pathol, 1990, 9: 129–136.PubMedCrossRefGoogle Scholar
- 6.Spanos WJ Jr, Peters LJ, Oswald MJ. Patterns of recurrence in malignant mixed müllerian tumor of the uterus. Cancer, 1986, 57: 155–159.PubMedCrossRefGoogle Scholar
- 7.Gonzalez Bosquet J, Terstriep SA, Cliby WA, et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol, 2010, 116: 419–423.PubMedCrossRefGoogle Scholar
- 8.Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys, 2004, 58: 786–796.PubMedCrossRefGoogle Scholar
- 9.Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 2005, 96: 630–634PubMedCrossRefGoogle Scholar
- 10.Ho KC, Lai CH, Wu TI, et al. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging, 2008, 35: 484–492.PubMedCrossRefGoogle Scholar